Advisory Board of Medical Directors

Christopher M. Palmer, M.D.

McLean Hospital Title:
  • Director, Department of Postgraduate and Continuing Education
Harvard Medical School Title:
  • Assistant Professor of Psychiatry

Biography:

Christopher M. Palmer, MD, received his medical degree from Washington University School of Medicine and completed his internship and psychiatry residency at McLean Hospital, Massachusetts General Hospital, and Harvard Medical School. He is currently the director of the Department of Postgraduate and Continuing Education at McLean Hospital and an assistant professor of psychiatry at Harvard Medical School.



Jay Lombard, M.D. 

Neurologist
Behavioral Neurology

Dr. Jay Lombard, is a Behavioral Neurologist seeing patients at Spectrum Neuroscience.  He is also co-founder of Genomind, a precision medicine company for psychiatry and mental health.

Prior to co-founding Genomind, Dr Lombard served as chief of Neurology at Bronx Lebanon Hospital between 2007-2011. He was also the head of the stroke division at the medical center, and has previously held academic medical appointments at New York Presbyterian Hospital and Albert Einstein College of Medicine.

Dr. Lombard served as chief of Neurology at Westchester Square Medical Center from 1995-2000, and at the Brain Behavior Center in Rockland County, NY, from 2000-2007, where he specialized in patients with intractable neurological and psychiatric disorders. He has been honored as one of the top Neurologists in NY. More recently, Dr. Lombard has held the position as Chief Medical Officer for the Cure Batten’s Disease Foundation. In this capacity, Dr. Lombard helped lead a team of researchers at Nationwide Children’s Hospital to develop the first human intrathecal gene trial for Batten’s disease approved by the FDA.



Jay Lombard, M.D. 

Neurologist
Behavioral Neurology

Dr. Jay Lombard, is a Behavioral Neurologist seeing patients at Spectrum Neuroscience.  He is also co-founder of Genomind, a precision medicine company for psychiatry and mental health.

Prior to co-founding Genomind, Dr Lombard served as chief of Neurology at Bronx Lebanon Hospital between 2007-2011. He was also the head of the stroke division at the medical center, and has previously held academic medical appointments at New York Presbyterian Hospital and Albert Einstein College of Medicine.

Dr. Lombard served as chief of Neurology at Westchester Square Medical Center from 1995-2000, and at the Brain Behavior Center in Rockland County, NY, from 2000-2007, where he specialized in patients with intractable neurological and psychiatric disorders. He has been honored as one of the top Neurologists in NY. More recently, Dr. Lombard has held the position as Chief Medical Officer for the Cure Batten’s Disease Foundation. In this capacity, Dr. Lombard helped lead a team of researchers at Nationwide Children’s Hospital to develop the first human intrathecal gene trial for Batten’s disease approved by the FDA.



Jay Lombard, M.D. 

Neurologist
Behavioral Neurology

Dr. Jay Lombard, is a Behavioral Neurologist seeing patients at Spectrum Neuroscience.  He is also co-founder of Genomind, a precision medicine company for psychiatry and mental health.

Prior to co-founding Genomind, Dr Lombard served as chief of Neurology at Bronx Lebanon Hospital between 2007-2011. He was also the head of the stroke division at the medical center, and has previously held academic medical appointments at New York Presbyterian Hospital and Albert Einstein College of Medicine.

Dr. Lombard served as chief of Neurology at Westchester Square Medical Center from 1995-2000, and at the Brain Behavior Center in Rockland County, NY, from 2000-2007, where he specialized in patients with intractable neurological and psychiatric disorders. He has been honored as one of the top Neurologists in NY. More recently, Dr. Lombard has held the position as Chief Medical Officer for the Cure Batten’s Disease Foundation. In this capacity, Dr. Lombard helped lead a team of researchers at Nationwide Children’s Hospital to develop the first human intrathecal gene trial for Batten’s disease approved by the FDA.